Shape Therapeutics is at the forefront of programmable RNA medicine, leveraging a unique combination of artificial intelligence (AI), RNA technology, and synthetic biology to develop innovative therapies. Their Shape TX platform utilizes an AI engine to analyze extensive datasets, enabling intelligent decision-making in the discovery and design of new RNA-based medicines. This platform harnesses the therapeutic potential of RNA by reprogramming cellular machinery to address the root causes of various diseases, making it possible to create safe, effective, and easily manufacturable treatments.

One of the key technologies employed by Shape Therapeutics is RNAfix®, which recruits the naturally occurring enzyme ADAR to correct or modify RNA instructions for protein synthesis without altering DNA. This approach allows for the correction of genetic mutations and the treatment of a wide range of genetic disorders. Additionally, the company has developed an advanced delivery system that engineers viral capsids for precise targeting of RNA medicines to specific tissues, minimizing potential side effects. Their TruStable™ stable cell lines enhance the scalability of RNA medicine manufacturing, ensuring that these innovative therapies can be produced in sufficient quantities to meet patient needs.

United States

Shape Therapeutics is a biotechnology company that combines breakthroughs in AI, RNA technology, and synthetic biology to create safe, effective, and accessible medicines to help as many patients as possible. The company was founded with the mission to make programmable RNA medicines available for everyone. Shape Therapeutics is pioneering the field of programmable RNA Medicines.

Shape Therapeutics

Company Details